MYR is the first private German biotech company to successfully take a drug from preclinical development to market. MYR’s lead compound ‘Bulevirtide’, sold under the brand name HepcludexTM, is a first-in-class entry inhibitor for the treatment of the most severe form of viral hepatitis, chronic hepatitis D (HDV).
Biotechnology, Health Care, Pharmaceutical
No funding announced yet
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as MYR GmbH? We’re happy to assist you with our Startup Sourcing service.